Overview

A Study of E2007 In Patients With Parkinson's Disease

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only. Patients who completed Study E2007-A001-214 (Cohorts I and II) and who meet inclusion/exclusion criteria will be enrolled and enter the 12-week Titration Phase (from "Dispense Study Drug" at Week 0 [Visit 2] through Week 12 [Visit 7]) followed by the Maintenance Phase (from Week 12 [Visit 7] to end of study).
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.